Literature DB >> 15806380

Extracellular matrix proteins and matrix metalloproteinases differ between various right and left ventricular sites in end-stage cardiomyopathies.

E Herpel1, S Singer, C Flechtenmacher, M Pritsch, F-U Sack, S Hagl, H A Katus, M Haass, H F Otto, P A Schnabel.   

Abstract

This study was undertaken to investigate whether there might be differences in the distribution of extracellular matrix (ECM) proteins and matrix metalloproteinases (MMPs), depending on their specific sites within the heart. We investigated 33 explanted human hearts, 15 with dilated cardiomyopathy (DCM) and 18 with ischemic cardiomyopathy (ICM). Transmural samples from the right ventricle, the interventricular septum and the left ventricle, either from near the apex or from near the base were taken from every heart. Frozen sections were processed for connective tissue staining and immunohistochemistry for collagens type I, III, IV, laminin and fibronectin, as well as MMP-1, -2 and -9. Volume densities of laminin in ICM as well as of fibronectin and collagen types I and IV in DCM showed significant differences between right and left ventricular sites. The volume densities of matrix proteins usually did not reveal significant differences among the three left ventricular sites tested in both DCM and ICM. MMPs partly showed differences between the right and the left ventricular myocardium. These results suggest that the distributions of ECM proteins and MMPs differ between the two ventricles in both end-stage DCM and ICM. This gives rise to the hypothesis that a specific pattern of ECM degradation exists in the right and left ventricular myocardium.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15806380     DOI: 10.1007/s00428-004-1177-z

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  35 in total

1.  Defects in matrix metalloproteinase inhibitory stoichiometry and selective MMP induction in patients with nonischemic or ischemic dilated cardiomyopathy.

Authors:  M L Coker; J L Zellner; A J Crumbley; F G Spinale
Journal:  Ann N Y Acad Sci       Date:  1999-06-30       Impact factor: 5.691

2.  Emerging role of matrix metalloproteinases in the pathophysiology of cardiac diseases.

Authors:  J Díez
Journal:  Eur J Clin Invest       Date:  2002-05       Impact factor: 4.686

Review 3.  Extracellular matrix remodelling: the role of matrix metalloproteinases.

Authors:  Ivan Stamenkovic
Journal:  J Pathol       Date:  2003-07       Impact factor: 7.996

4.  Regeneration processes in human myocardium after acute ischaemia--quantitative determination of DNA, cell number and collagen content.

Authors:  C P Adler; M Neuburger; G W Herget; D Mühlbach
Journal:  Virchows Arch       Date:  1997-02       Impact factor: 4.064

5.  Dilated cardiomyopathy is associated with significant changes in collagen type I/III ratio.

Authors:  M Pauschinger; D Knopf; S Petschauer; A Doerner; W Poller; P L Schwimmbeck; U Kühl; H P Schultheiss
Journal:  Circulation       Date:  1999-06-01       Impact factor: 29.690

6.  Optimizing sampling efficiency of stereological studies in biology: or 'do more less well!'.

Authors:  H J Gundersen; R Osterby
Journal:  J Microsc       Date:  1981-01       Impact factor: 1.758

7.  Leukaemia inhibitory factor alters expression of genes involved in rat cardiomyocyte energy metabolism.

Authors:  G Florholmen; K B Andersson; A Yndestad; B Austbø; U L Henriksen; G Christensen
Journal:  Acta Physiol Scand       Date:  2004-02

8.  Structural analysis of arteriolar and myocardial remodelling in the subendocardial region of patients with hypertensive heart disease and hypertrophic cardiomyopathy.

Authors:  M Mundhenke; B Schwartzkopff; B E Strauer
Journal:  Virchows Arch       Date:  1997-10       Impact factor: 4.064

9.  Differential expression of tissue inhibitors of metalloproteinases in the failing human heart.

Authors:  Y Y Li; A M Feldman; Y Sun; C F McTiernan
Journal:  Circulation       Date:  1998-10-27       Impact factor: 29.690

10.  Measuring extracellular matrix turnover in the serum of patients with idiopathic or ischemic dilated cardiomyopathy and impact on diagnosis and prognosis.

Authors:  G Klappacher; P Franzen; D Haab; M Mehrabi; M Binder; K Plesch; R Pacher; M Grimm; I Pribill; H G Eichler
Journal:  Am J Cardiol       Date:  1995-05-01       Impact factor: 2.778

View more
  9 in total

1.  Engineered heart slices for electrophysiological and contractile studies.

Authors:  Adriana Blazeski; Geran M Kostecki; Leslie Tung
Journal:  Biomaterials       Date:  2015-04-17       Impact factor: 12.479

Review 2.  Changes in the myocardial interstitium and contribution to the progression of heart failure.

Authors:  Shaina R Eckhouse; Francis G Spinale
Journal:  Heart Fail Clin       Date:  2012-01       Impact factor: 3.179

3.  Right ventricular expression of extracellular matrix proteins, matrix-metalloproteinases, and their inhibitors over a period of 3 years after heart transplantation.

Authors:  D J Schupp; B P Huck; J Sykora; C Flechtenmacher; M Gorenflo; A Koch; F-U Sack; M Haass; H A Katus; H E Ulmer; S Hagl; H F Otto; P A Schnabel
Journal:  Virchows Arch       Date:  2005-09-14       Impact factor: 4.064

Review 4.  Cardiac Fibrosis in the Pressure Overloaded Left and Right Ventricle as a Therapeutic Target.

Authors:  Katharina Schimmel; Kenzo Ichimura; Sushma Reddy; Francois Haddad; Edda Spiekerkoetter
Journal:  Front Cardiovasc Med       Date:  2022-05-06

5.  Infiltration of inflammatory cells plays an important role in matrix metalloproteinase expression and activation in the heart during sepsis.

Authors:  Jimena Cuenca; Paloma Martín-Sanz; Alberto M Alvarez-Barrientos; Lisardo Boscá; Nora Goren
Journal:  Am J Pathol       Date:  2006-11       Impact factor: 4.307

Review 6.  Basement membrane components are key players in specialized extracellular matrices.

Authors:  Jenny Kruegel; Nicolai Miosge
Journal:  Cell Mol Life Sci       Date:  2010-04-29       Impact factor: 9.261

7.  Increased cardiac mRNA expression of matrix metalloproteinase-1 (MMP-1) and its inhibitor (TIMP-1) in DCM patients.

Authors:  F Picard; M Brehm; M Fassbach; B Pelzer; S Scheuring; P Küry; B E Strauer; B Schwartzkopff
Journal:  Clin Res Cardiol       Date:  2006-04-03       Impact factor: 6.138

Review 8.  Treatment Targets for Right Ventricular Dysfunction in Pulmonary Arterial Hypertension.

Authors:  Sasha Z Prisco; Thenappan Thenappan; Kurt W Prins
Journal:  JACC Basic Transl Sci       Date:  2020-12-28

Review 9.  Exploring Functional Differences between the Right and Left Ventricles to Better Understand Right Ventricular Dysfunction.

Authors:  Judith Bernal-Ramirez; Magda C Díaz-Vesga; Matias Talamilla; Andrea Méndez; Clara Quiroga; Javier A Garza-Cervantes; Anay Lázaro-Alfaro; Carlos Jerjes-Sanchez; Mauricio Henríquez; Gerardo García-Rivas; Zully Pedrozo
Journal:  Oxid Med Cell Longev       Date:  2021-08-28       Impact factor: 6.543

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.